Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”

Samankaltaisia teoksia

• Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada
  Tekijä: Wilson, Michele, et al.
  Julkaistu: (2018)
• Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium
  Tekijä: Wasserman, Matt D., et al.
  Julkaistu: (2018)
• Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
  Tekijä: Earnshaw, Stephanie R, et al.
  Julkaistu: (2012)
• Pneumococcal Vaccination Provides Substantial Value for Money for Canadians
  Tekijä: Peloquin, Francois, et al.
  Julkaistu: (2017)
• Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
  Tekijä: Wasserman, Matt, et al.
  Julkaistu: (2019)